UPDATE 1-New Roche haemophilia drug prevents bleeds but questions remain

ZURICH, June 26 (Reuters) – Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Original Article